Patient Profiles in HER2-Positive Breast Cancer

Experts engage in discussion on patient profiles to review updated treatment approaches and sequencing in patients with HER2-positive metastatic breast cancer.

EP. 1: HER2+ Breast Cancer: Overview of the Treatment Armamentarium

April 1st 2022

Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.

EP. 2: Selecting and Sequencing Therapy for HER2+ Breast Cancer

April 1st 2022

Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.

EP. 3: Recent Trial Data in HER2+ Metastatic Breast Cancer

April 8th 2022

Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.

EP. 4: Patient Profile 1: Frontline Therapy for HER2+ mBC

April 8th 2022

Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.

EP. 5: Patient Profile 1: Second-Line Therapy for HER2+ mBC

April 15th 2022

Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.

EP. 6: Patient Profile 1: Sequencing Therapies in HER2+ mBC

April 15th 2022

Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.

EP. 7: Patient Profile 2: Patient with Triple-Positive mBC

April 22nd 2022

Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.

EP. 8: Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

April 22nd 2022

Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.

EP. 9: Patient Profile 2: 3L Therapy for Triple-Positive mBC

April 29th 2022

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

EP. 10: Considering Novel Therapy for HER2+ Metastatic Breast Cancer

April 29th 2022

A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.

EP. 11: Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

May 19th 2022

Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.

EP. 12: Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

May 19th 2022

Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.

EP. 13: Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

May 26th 2022

Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.

EP. 14: Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

May 26th 2022

Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.

EP. 15: Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?

June 1st 2022

Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.

EP. 16: Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC

June 1st 2022

Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.

EP. 17: Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

June 8th 2022

Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.

EP. 18: Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

June 8th 2022

Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.

EP. 19: Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

June 15th 2022

Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.

EP. 20: Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

June 15th 2022

Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.